ProShares Ultra Bloomberg Natural Gas

VS TR 2x Long VIX Futures ETF

Direxion Daily S&P Biotech Bear 3X ETF

Direxion Daily Small Cap Bear 3X ETF

Direxion Daily 20+ Yr Trsy Bear 3X ETF

ProShares Ultra VIX Short-Term Futures

ProShares UltraPro Short S&P500

iPath S&P 500 VIX ST Futures ETN

United States Natural Gas

Direxion Daily Semicondct Bear 3X ETF

Bank Of Montreal

ProShares UltraShort Bloomberg Natrl Gas

Bank Of Montreal MAX S&P 500 4X Leveraged ETNs due October 30

GraniteShares 1.5x Long META Daily ETF

Direxion Daily Small Cap Bull 3X ETF

Direxion Daily S&P Biotech Bull 3X ETF

Direxion Daily 20+ Yr Trsy Bull 3X ETF

GraniteShares 1.5x Long NVDA Daily ETF

ProShares UltraPro Dow30

Direxion Daily Semicondct Bull 3X ETF

Edible Garden AG Incorporated Common Stock

SBA Communications Corporation Class A Common Stock

D-Wave Quantum Inc. Common Shares

Dycom Industries Inc. Common Stock

Ascentage Pharma Group International American Depository Shares

Trio Petroleum Corp. Common Stock

AgEagle Aerial Systems Inc. Common Stock

Pony AI Inc. American Depositary Shares

XPeng Inc. American depositary shares each representing two Class A ordinary shares

Protagenic Therapeutics Inc. Common Stock

Siyata Mobile Inc. Common Shares

Neuraxis Inc. Common Stock

Sensata Technologies Holding plc Ordinary Shares

Carter's Inc. Common Stock

NWTN Inc. Class B Ordinary Shares

Aytu BioPharma Inc.  Common Stock

AST SpaceMobile Inc. Class A Common Stock

Palo Alto Networks Inc. Common Stock

Arcturus Therapeutics Holdings Inc. Common Stock

Nuvve Holding Corp. Common Stock

Click here to get full coverage on Roivant tightens grip on Immunovant as IMVT-1402 takes centre stage - FirstWord Pharma

Roivant tightens grip on Immunovant as IMVT-1402 takes centre stage  FirstWord Pharma

Roivant tightens grip on Immunovant as IMVT-1402 takes centre stage - FirstWord Pharma

Click here to get full coverage on Immunovant's Major Growth Push: Drug Pipeline Hits 6 Indications as Roivant Executive Takes CEO Role - Stock Titan

Immunovant's Major Growth Push: Drug Pipeline Hits 6 Indications as Roivant Executive Takes CEO Role  Stock Titan

Immunovant's Major Growth Push: Drug Pipeline Hits 6 Indications as Roivant Executive Takes CEO Role - Stock Titan

Click here to get full coverage on Is Immunovant, Inc. (IMVT) The Most Undervalued Stock With Smart Money Ratings? - Insider Monkey

Is Immunovant, Inc. (IMVT) The Most Undervalued Stock With Smart Money Ratings?  Insider Monkey

Is Immunovant, Inc. (IMVT) The Most Undervalued Stock With Smart Money Ratings? - Insider Monkey

Click here to get full coverage on (IMVT) Investment Analysis - news.stocktradersdaily.com

(IMVT) Investment Analysis  news.stocktradersdaily.com

(IMVT) Investment Analysis - news.stocktradersdaily.com

Click here to get full coverage on Immunovant, Inc. (IMVT): Among The Stocks With At Least $30 Million In Insider Spending Recently - Yahoo Finance

Immunovant, Inc. (IMVT): Among The Stocks With At Least $30 Million In Insider Spending Recently  Yahoo Finance

Immunovant, Inc. (IMVT): Among The Stocks With At Least $30 Million In Insider Spending Recently - Yahoo Finance

Click here to get full coverage on Trial of Sjögren's treatment IMVT-1402 slated to launch in summer - Sjogren's Syndrome News

Trial of Sjögren's treatment IMVT-1402 slated to launch in summer  Sjogren's Syndrome News

Trial of Sjögren's treatment IMVT-1402 slated to launch in summer - Sjogren's Syndrome News

Click here to get full coverage on Immunovant will not seek approval for MG therapy, despite hitting endpoints - Clinical Trials Arena

Immunovant will not seek approval for MG therapy, despite hitting endpoints  Clinical Trials Arena

Immunovant will not seek approval for MG therapy, despite hitting endpoints - Clinical Trials Arena

Click here to get full coverage on Immunovant, Inc. Reports Progress on IMVT-1402 Development and Financial Results for Fiscal Q3 2024 - Nasdaq

Immunovant, Inc. Reports Progress on IMVT-1402 Development and Financial Results for Fiscal Q3 2024  Nasdaq

Immunovant, Inc. Reports Progress on IMVT-1402 Development and Financial Results for Fiscal Q3 2024 - Nasdaq

Click here to get full coverage on Immunovant won't seek approval for autoimmune drug despite phase 3 win - Fierce Biotech

Immunovant won't seek approval for autoimmune drug despite phase 3 win  Fierce Biotech

Immunovant won't seek approval for autoimmune drug despite phase 3 win - Fierce Biotech

Click here to get full coverage on Immunovant claims study success for immune disease drug but holds off on submission - BioPharma Dive

Immunovant claims study success for immune disease drug but holds off on submission  BioPharma Dive

Immunovant claims study success for immune disease drug but holds off on submission - BioPharma Dive

Click here to get full coverage on Why This Biotech Just Underwent A Surprise C-Suite Sweep - Investor's Business Daily

Why This Biotech Just Underwent A Surprise C-Suite Sweep  Investor's Business Daily

Why This Biotech Just Underwent A Surprise C-Suite Sweep - Investor's Business Daily

Click here to get full coverage on Immunovant's Massive $825M War Chest Fuels Race for Breakthrough Autoimmune Treatments - Stock Titan

Immunovant's Massive $825M War Chest Fuels Race for Breakthrough Autoimmune Treatments  Stock Titan

Immunovant's Massive $825M War Chest Fuels Race for Breakthrough Autoimmune Treatments - Stock Titan

Click here to get full coverage on Is Immunovant, Inc. (IMVT) the Best Low Cost Stock to Buy According to Billionaires? - Yahoo Finance

Is Immunovant, Inc. (IMVT) the Best Low Cost Stock to Buy According to Billionaires?  Yahoo Finance

Is Immunovant, Inc. (IMVT) the Best Low Cost Stock to Buy According to Billionaires? - Yahoo Finance

Click here to get full coverage on Immunovant touts positive Phase II batoclimab data as IMVT-1402 also progresses - Clinical Trials Arena

Immunovant touts positive Phase II batoclimab data as IMVT-1402 also progresses  Clinical Trials Arena

Immunovant touts positive Phase II batoclimab data as IMVT-1402 also progresses - Clinical Trials Arena

Click here to get full coverage on Immunovant (IMVT) Loses -15.47% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner - Nasdaq

Immunovant (IMVT) Loses -15.47% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner  Nasdaq

Immunovant (IMVT) Loses -15.47% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner - Nasdaq

Click here to get full coverage on Here’s Why Immunovant, Inc. (IMVT) Will Double in 2025 - Yahoo Finance

Here’s Why Immunovant, Inc. (IMVT) Will Double in 2025  Yahoo Finance

Here’s Why Immunovant, Inc. (IMVT) Will Double in 2025 - Yahoo Finance

Click here to get full coverage on Immunovant Advances IMVT-1402 with 5 IND Clearances Despite Widening Losses - Stock Titan

Immunovant Advances IMVT-1402 with 5 IND Clearances Despite Widening Losses  Stock Titan

Immunovant Advances IMVT-1402 with 5 IND Clearances Despite Widening Losses - Stock Titan

Click here to get full coverage on Immunovant, Inc. (IMVT): the Most Oversold Pharma Stock to Buy According to Analysts - Yahoo Finance

Immunovant, Inc. (IMVT): the Most Oversold Pharma Stock to Buy According to Analysts  Yahoo Finance

Immunovant, Inc. (IMVT): the Most Oversold Pharma Stock to Buy According to Analysts - Yahoo Finance

Click here to get full coverage on IMVT Unlikely to Pursue Batoclimab for MG & CIDP Despite Success - Yahoo Finance

IMVT Unlikely to Pursue Batoclimab for MG & CIDP Despite Success  Yahoo Finance

IMVT Unlikely to Pursue Batoclimab for MG & CIDP Despite Success - Yahoo Finance

Click here to get full coverage on We Think Immunovant (NASDAQ:IMVT) Can Afford To Drive Business Growth - Yahoo Finance

We Think Immunovant (NASDAQ:IMVT) Can Afford To Drive Business Growth  Yahoo Finance

We Think Immunovant (NASDAQ:IMVT) Can Afford To Drive Business Growth - Yahoo Finance

Click here to get full coverage on All change at Immunovant as Pete Salzmann retires - The Pharma Letter

All change at Immunovant as Pete Salzmann retires  The Pharma Letter

All change at Immunovant as Pete Salzmann retires - The Pharma Letter

Click here to get full coverage on Batoclimab eases disease severity; Immunovant backs IMVT-1402 - Myasthenia Gravis News

Batoclimab eases disease severity; Immunovant backs IMVT-1402  Myasthenia Gravis News

Batoclimab eases disease severity; Immunovant backs IMVT-1402 - Myasthenia Gravis News

Click here to get full coverage on Why Is Immunovant, Inc. (IMVT) Among the Worst Performing Biotech Stocks in 2024? - Yahoo Finance

Why Is Immunovant, Inc. (IMVT) Among the Worst Performing Biotech Stocks in 2024?  Yahoo Finance

Why Is Immunovant, Inc. (IMVT) Among the Worst Performing Biotech Stocks in 2024? - Yahoo Finance

Click here to get full coverage on Immunovant Secures Massive $450M Private Placement to Accelerate Drug Development - Stock Titan

Immunovant Secures Massive $450M Private Placement to Accelerate Drug Development  Stock Titan

Immunovant Secures Massive $450M Private Placement to Accelerate Drug Development - Stock Titan

Click here to get full coverage on Biotechs Rise After Putting Phase 3 Winner On Back Burner - Investor's Business Daily

Biotechs Rise After Putting Phase 3 Winner On Back Burner  Investor's Business Daily

Biotechs Rise After Putting Phase 3 Winner On Back Burner - Investor's Business Daily

Click here to get full coverage on Roivant Tightens Leadership Grip On Immunovant, Narrows Near-Term IMVT-1402 Focus - insights.citeline.com

Roivant Tightens Leadership Grip On Immunovant, Narrows Near-Term IMVT-1402 Focus  insights.citeline.com

Roivant Tightens Leadership Grip On Immunovant, Narrows Near-Term IMVT-1402 Focus - insights.citeline.com

Click here to get full coverage on Immunovant: TED Data Sets Stage For Batoclimab Regulatory Filings Going Forward (IMVT) - Seeking Alpha

Immunovant: TED Data Sets Stage For Batoclimab Regulatory Filings Going Forward (IMVT)  Seeking Alpha

Immunovant: TED Data Sets Stage For Batoclimab Regulatory Filings Going Forward (IMVT) - Seeking Alpha

Click here to get full coverage on Immunovant Will Drop One Myasthenia Gravis Asset, Continuing to Favor Another - BioSpace

Immunovant Will Drop One Myasthenia Gravis Asset, Continuing to Favor Another  BioSpace

Immunovant Will Drop One Myasthenia Gravis Asset, Continuing to Favor Another - BioSpace

Click here to get full coverage on Is Immunovant, Inc. (IMVT) The Best Stock That Will Bounce Back? - Insider Monkey

Is Immunovant, Inc. (IMVT) The Best Stock That Will Bounce Back?  Insider Monkey

Is Immunovant, Inc. (IMVT) The Best Stock That Will Bounce Back? - Insider Monkey

Click here to get full coverage on Despite Phase III success in myasthenia gravis, Immunovant shifts to successor drug - FirstWord Pharma

Despite Phase III success in myasthenia gravis, Immunovant shifts to successor drug  FirstWord Pharma

Despite Phase III success in myasthenia gravis, Immunovant shifts to successor drug - FirstWord Pharma

Click here to get full coverage on Immunovant, Roivant slip after trial data for autoimmune disorder therapy - Seeking Alpha

Immunovant, Roivant slip after trial data for autoimmune disorder therapy  Seeking Alpha

Immunovant, Roivant slip after trial data for autoimmune disorder therapy - Seeking Alpha

Click here to get full coverage on SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Immunovant, Inc. (NASDAQ: IMVT) - PR Newswire

SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Immunovant, Inc. (NASDAQ: IMVT)  PR Newswire

SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Immunovant, Inc. (NASDAQ: IMVT) - PR Newswire

Click here to get full coverage on Smart Money Ratings For 20 Most Undervalued Stocks - Insider Monkey

Smart Money Ratings For 20 Most Undervalued Stocks  Insider Monkey

Smart Money Ratings For 20 Most Undervalued Stocks - Insider Monkey

Click here to get full coverage on Positive batoclimab data from Immunovant, but doubts raised on further development - The Pharma Letter

Positive batoclimab data from Immunovant, but doubts raised on further development  The Pharma Letter

Positive batoclimab data from Immunovant, but doubts raised on further development - The Pharma Letter

Click here to get full coverage on Immunovant price target raised to $61 from $58 at Stifel - Yahoo Finance

Immunovant price target raised to $61 from $58 at Stifel  Yahoo Finance

Immunovant price target raised to $61 from $58 at Stifel - Yahoo Finance

Click here to get full coverage on (IMVT) Investment Report - news.stocktradersdaily.com

(IMVT) Investment Report  news.stocktradersdaily.com

(IMVT) Investment Report - news.stocktradersdaily.com

Click here to get full coverage on Immunovant Announces Next Phase of Growth with Roivant Including Changes to its Leadership Team and Additional Indications Sjögren’s Disease (SjD) and Cutaneous Lupus Erythematosus (CLE) for IMVT-1402 - Yahoo Finance

Immunovant Announces Next Phase of Growth with Roivant Including Changes to its Leadership Team and Additional Indications Sjögren’s Disease (SjD) and Cutaneous Lupus Erythematosus (CLE) for IMVT-1402  Yahoo Finance

Immunovant Announces Next Phase of Growth with Roivant Including Changes to its Leadership Team and Additional Indications Sjögren’s Disease (SjD) and Cutaneous Lupus Erythematosus (CLE) for IMVT-1402 - Yahoo Finance

Click here to get full coverage on Immunovant’s batoclimab shows ‘impressive’ efficacy in MG, says H.C. Wainwright - Yahoo Finance

Immunovant’s batoclimab shows ‘impressive’ efficacy in MG, says H.C. Wainwright  Yahoo Finance

Immunovant’s batoclimab shows ‘impressive’ efficacy in MG, says H.C. Wainwright - Yahoo Finance

Click here to get full coverage on Immunovant narrows R&D focus as Roivant execs take CEO, CFO posts - Fierce Biotech

Immunovant narrows R&D focus as Roivant execs take CEO, CFO posts  Fierce Biotech

Immunovant narrows R&D focus as Roivant execs take CEO, CFO posts - Fierce Biotech

Click here to get full coverage on Updated: Immunovant will not take rare disease drug to regulators despite Phase 3 win - Endpoints News

Updated: Immunovant will not take rare disease drug to regulators despite Phase 3 win  Endpoints News

Updated: Immunovant will not take rare disease drug to regulators despite Phase 3 win - Endpoints News

Click here to get full coverage on Phase 3 trial of IMVT-1402 for MG advancing, with March as goal - Myasthenia Gravis News

Phase 3 trial of IMVT-1402 for MG advancing, with March as goal  Myasthenia Gravis News

Phase 3 trial of IMVT-1402 for MG advancing, with March as goal - Myasthenia Gravis News

Click here to get full coverage on How the (IMVT) price action is used to our Advantage - news.stocktradersdaily.com

How the (IMVT) price action is used to our Advantage  news.stocktradersdaily.com

How the (IMVT) price action is used to our Advantage - news.stocktradersdaily.com

Click here to get full coverage on (IMVT) On The My Stocks Page - news.stocktradersdaily.com

(IMVT) On The My Stocks Page  news.stocktradersdaily.com

(IMVT) On The My Stocks Page - news.stocktradersdaily.com

Click here to get full coverage on Long Term Trading Analysis for (IMVT) - news.stocktradersdaily.com

Long Term Trading Analysis for (IMVT)  news.stocktradersdaily.com

Long Term Trading Analysis for (IMVT) - news.stocktradersdaily.com

Click here to get full coverage on Roivant brings rare disease program closer as Immunovant CEO retires - Endpoints News

Roivant brings rare disease program closer as Immunovant CEO retires  Endpoints News

Roivant brings rare disease program closer as Immunovant CEO retires - Endpoints News

Click here to get full coverage on Immunovant, Inc. (IMVT): Among Stocks Insiders Spent The Most Money On Recently - Insider Monkey

Immunovant, Inc. (IMVT): Among Stocks Insiders Spent The Most Money On Recently  Insider Monkey

Immunovant, Inc. (IMVT): Among Stocks Insiders Spent The Most Money On Recently - Insider Monkey

Click here to get full coverage on 11 Stocks That Will Bounce Back According to Analysts - Insider Monkey

11 Stocks That Will Bounce Back According to Analysts  Insider Monkey

11 Stocks That Will Bounce Back According to Analysts - Insider Monkey

Click here to get full coverage on Street View: Immunovant's muscle drug shows potential as analysts await data on lead candidate - TradingView

Street View: Immunovant's muscle drug shows potential as analysts await data on lead candidate  TradingView

Street View: Immunovant's muscle drug shows potential as analysts await data on lead candidate - TradingView

Click here to get full coverage on Immunovant Ditches Seeking FDA Approval For Batoclimab For Two Autoimmune Disorders Despite Positive Phase 3 Data - Yahoo Finance

Immunovant Ditches Seeking FDA Approval For Batoclimab For Two Autoimmune Disorders Despite Positive Phase 3 Data  Yahoo Finance

Immunovant Ditches Seeking FDA Approval For Batoclimab For Two Autoimmune Disorders Despite Positive Phase 3 Data - Yahoo Finance

Click here to get full coverage on Immunovant, Inc. (IMVT): Among Stocks Insiders Spent The Most Money On Recently - MSN

Immunovant, Inc. (IMVT): Among Stocks Insiders Spent The Most Money On Recently  MSN

Immunovant, Inc. (IMVT): Among Stocks Insiders Spent The Most Money On Recently - MSN

Click here to get full coverage on Immunovant Announces New CEO Amid Strategic Shift - TipRanks

Immunovant Announces New CEO Amid Strategic Shift  TipRanks

Immunovant Announces New CEO Amid Strategic Shift - TipRanks

Click here to get full coverage on Immunovant's Key Batoclimab Trial Catalysts Expected By March - Can The Stock Bounce Back? - RTTNews

Immunovant's Key Batoclimab Trial Catalysts Expected By March - Can The Stock Bounce Back?  RTTNews

Immunovant's Key Batoclimab Trial Catalysts Expected By March - Can The Stock Bounce Back? - RTTNews

Click here to get full coverage on Immunovant’s Competitive Edge and Growth Potential: Buy Rating Supported by IMVT-1402 Approval and Promising Study Results - TipRanks

Immunovant’s Competitive Edge and Growth Potential: Buy Rating Supported by IMVT-1402 Approval and Promising Study Results  TipRanks

Immunovant’s Competitive Edge and Growth Potential: Buy Rating Supported by IMVT-1402 Approval and Promising Study Results - TipRanks

Click here to get full coverage on Immunovant stock hits 52-week low at $13.58 amid market challenges - Investing.com

Immunovant stock hits 52-week low at $13.58 amid market challenges  Investing.com

Immunovant Inc (IMVT)

Price Chart

Key Statistics

Technicals

About IMVT

Latest News

Roivant tightens grip on Immunovant as IMVT-1402 takes centre stage - FirstWord Pharma

Immunovant's Major Growth Push: Drug Pipeline Hits 6 Indications as Roivant Executive Takes CEO Role - Stock Titan

Is Immunovant, Inc. (IMVT) The Most Undervalued Stock With Smart Money Ratings? - Insider Monkey

Advanced Charts

Top Gainers

Top Losers